Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Late-Onset Pompe Disease (LOPD) is a rare inherited metabolic disorder caused by deficient acid alpha-glucosidase, leading to progressive glycogen accumulation and muscle weakness. According to Weijing Kong et al. (2024), global birth prevalence of LOPD was 2.4 cases per 100,000 live births. As per the late-onset Pompe disease epidemiology forecast by Expert Market Research, continued epidemiological assessment supports disease understanding.
Base Year
Historical Period
Forecast Period

Read more about this report - Request a Free Sample
Expert Market Research's “Late-Onset Pompe Disease (LOPD) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of late-onset Pompe disease (LOPD). It projects the future incidence and prevalence rates of late-onset Pompe disease (LOPD) cases across various populations. The study covers age, gender, and type as major determinants of the late-onset Pompe disease (LOPD) population. The report highlights patterns in the prevalence of late-onset Pompe disease (LOPD) over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of late-onset Pompe disease (LOPD) in the 8 major markets.
Regions Covered
Late-onset Pompe disease (LOPD) is a rare inherited metabolic syndrome caused by pathogenic variants in the GAA gene, resulting in deficient acid alpha-glucosidase activity and progressive accumulation of glycogen within skeletal and respiratory muscles. It is an autosomal recessive disorder and represents one of the clinical forms of Pompe disease. Unlike infantile-onset disease, LOPD generally develops during childhood, adolescence, or adulthood and progresses more slowly. Common manifestations include progressive proximal muscle weakness, impaired mobility, and respiratory muscle involvement. Glycogen storage in muscle cells contributes to progressive tissue damage and functional decline.
|
Parameter |
Insight |
|
Largest Patient Pool |
United States |
|
Fastest Growing Country |
United States |
|
High-Risk Population |
Individuals with pathogenic GAA variants, particularly those with progressive skeletal or respiratory muscle weakness |
|
Key Diagnostic Method |
Enzyme activity testing supported by GAA genetic testing |
|
Major Risk Factor |
Deficiency of acid alpha-glucosidase leading to progressive glycogen accumulation |
|
Major gap in the market |
Delayed diagnosis and underdiagnosis |
The late-onset Pompe disease (LOPD) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the late-onset Pompe disease (LOPD) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for late-onset Pompe disease (LOPD) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
Global birth prevalence of late-onset Pompe disease was 2.4 cases per 100,000 live births, according to Weijing Kong et al., https://pubmed.ncbi.nlm.nih.gov/39424261/2024. |
|
Gender-Specific Cases of the Disease |
In an Italian pediatric cohort, males accounted for 63% (24/38) of late-onset Pompe disease patients, compared with 37% (14/38) females. As reported by Marco Spada et al., 2025, this distribution provides a gender-specific profile of diagnosed pediatric cases. |
|
Age-Specific Cases of the Disease |
The Italian pediatric cohort included patients diagnosed across childhood, with 26% (10/38) diagnosed at 0–3 years and 74% (28/38) at 3–18 years, according to Marco Spada et al., 2025, demonstrating diagnosis across different pediatric age groups. |
|
Ethnicity-Wise Cases of the Disease |
Epidemiological estimates vary across ethnic populations. According to Yutaka Furuta et al., 2025, Pompe disease was reported at approximately 1 in 14,000 among African Americans compared with 1 in 100,000 among individuals of European descent, indicating substantial population-level variation. |
|
Mortality and Survival Analysis of the Disease |
Late-onset Pompe disease is associated with a progressive epidemiological burden extending from childhood into adulthood. According to Yutaka Furuta et al., 2025, adult presentation may involve progressive respiratory and neuromuscular impairment, highlighting the importance of disease recognition across the lifespan. |

Read more about this report - Request a Free Sample
The late-onset Pompe disease (LOPD) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
The United States demonstrates variation in Pompe disease epidemiology across populations. According to Yutaka Furuta et al., 2025, incidence was approximately 1 in 40,000, with reported rates of 1 in 14,000 among African Americans and 1 in 100,000 among individuals of European descent, highlighting geographic and population-level variation. |
|
Germany |
Germany contributes to the broader European epidemiological landscape of Pompe disease, where estimates can vary according to population characteristics and diagnostic approaches. As per Roberto Giugliani et al., 2025, differences in screening and diagnostic methodologies contribute to variation in reported epidemiological estimates across geographic regions. |
|
France |
France has demonstrated an increasing pattern of late-onset Pompe disease diagnosis over time. According to Roberto Giugliani et al., 2025, the French National Pompe Registry recorded diagnoses increasing. |
|
Italy |
Italy has documented a defined pediatric late-onset Pompe disease population. According to Marco Spada et al., 2025, 38 pediatric patients were identified, including 63% males and 37% females; 26% were diagnosed at 0–3 years and 74% at 3–18 years. |
|
Spain |
Spain forms part of the European epidemiological context in which Pompe disease estimates vary according to geographic population characteristics and diagnostic approaches. Based on the provided evidence, the epidemiological profile is characterized by the broader European pattern of variation in disease identification and diagnosis. |
|
United Kingdom |
The United Kingdom forms part of the European Pompe disease epidemiological landscape. According to Roberto Giugliani et al., 2025, epidemiological estimates across regions are influenced by differences in diagnostic methods, screening approaches, and disease classification, factors relevant to interpretation of regional disease burden. |
|
Japan |
Japan demonstrates distinct epidemiological patterns within Asian populations. According to Roberto Giugliani et al., 2025, newborn-screening studies reported infantile-onset Pompe disease birth prevalence of 1 in 297,387, while Asian populations have also demonstrated a higher frequency of pseudodeficiency alleles. |
|
India |
India represents an Asian population within the broader geographic variation observed for Pompe disease epidemiology. As per Roberto Giugliani et al., 2025, epidemiological estimates can vary across geographic and ethnic populations, while differences in screening and diagnostic practices influence identification of affected individuals. |
The regional disease epidemiology landscape for Late-Onset Pompe Disease is characterized by persistent underdiagnosis and delayed diagnosis, largely because its symptoms can overlap with other neuromuscular disorders. Limited disease awareness among healthcare professionals and the rarity of the condition can further delay referral for confirmatory testing. An important opportunity exists to strengthen diagnostic pathways through greater use of enzyme activity testing and molecular confirmation, particularly in patients presenting with unexplained progressive muscle weakness or respiratory dysfunction. Expanding specialist networks and improving access to enzyme replacement therapy may also support earlier intervention across the United States, European markets, Japan, and India.
Late-onset Pompe disease treatment primarily focuses on reducing glycogen accumulation, preserving muscle function, and slowing disease progression. Enzyme replacement therapy (ERT) is the principal disease-specific treatment and involves intravenous administration of recombinant acid alpha-glucosidase to supplement deficient enzyme activity. Available ERT options include alglucosidase alfa and newer enzyme formulations, depending on regulatory approval and clinical availability. Supportive management is also important and may include respiratory support, physical therapy, exercise programs, nutritional management, and mobility assistance. Regular assessment of respiratory, motor, and swallowing function helps guide individualized treatment and disease monitoring.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.